Treatment of Multicentric Castleman's disease accompanying multiple myeloma with bortezomib: A case report

Journal of Hematology and Oncology

Volumn 2, Issue , 2009, Pages

  Yuan, Zhen Gang ^a   Dun, Xiao Yi ^a   Li, Yong Hua ^a   Hou, Jian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ABDOMINAL DISTENSION; AGED; ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CELL STRUCTURE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; ECHOGRAPHY; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOELECTROPHORESIS; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LYMPHADENOPATHY; MALE; MULTICENTRIC CASTLEMAN DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PERIPHERAL LYMPHADENOPATHY; PETECHIA; PHYSICAL EXAMINATION; SPLENOMEGALY; THYROID FUNCTION TEST; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME; ULTRASOUND; WEIGHT REDUCTION; MULTIPLE CANCER; PATHOLOGY; REMISSION;

AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; GIANT LYMPH NODE HYPERPLASIA; HUMANS; MALE; MULTIPLE MYELOMA; NEOPLASMS, MULTIPLE PRIMARY; PYRAZINES; REMISSION INDUCTION;

EID: 67651184064     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-2-19     Document Type: Article

References (19)

1. Gaba AR, Stein RS, Sweet DL, Variakojis D: Multicentric giant lymph node hyperplasia. American Journal of Clinical Pathology 1978, 69:86-90.
2. Jongsma TEF, Verburg RJ, Geelhoed-Duijvestijn PH: Castleman's disease: A rare lymphoproliferative disorder. European Journal of Internal Medicine 2007, 18:87-89.
3. Kropff M, Bisping G, Wenning D, Berdel W, Kienast J: Protesome inhibition in multiple myeloma. Eur J Cancer 2006, 42:1623-1639.
4. Komatsu M, Ehara T, Kuroda T: Cervical Castleman's Disease Associated with Benign M-proteinemia: Report of a Case. Surg Today Jpn J Surg 1996, 26:213-216.
5. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T: Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989, 74:1360-1367.
6. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W: The clinical behavior of localized and multicentric Castleman's disease. Annals of Internal Medicine 1998, 128:657-662.
7. Frizzera G, Peterson BA, Bayrd ED, Goldman A: A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. Journal of Clinical Oncology 1985, 3:1202-1216.
8. Kumari P, Schechter GP, Saini N, Benator DA: Successful treatment of human immunodeficiency virus-related Castleman's disease with interferon-alpha. Clinical Infectious Diseases 2000, 31:602-604.
9. Casper C, Nichols WG, Huang ML, Corey L, Wald A: Remission of HHV-8 and HIV-associated multicentric Castleman's disease with ganciclovir treatment. Blood 2004, 103:1632-1634.
10. Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B: Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal antiinterleukin-6 antibody. N Engl J Med 1994, 330:602-605.
11. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T: Humanized anti-interleukin-6 receptor antibody treatment of Multicentric Castleman's disease. Blood 2005, 106 (8):2627-2632.
12. Rieu P, Droz D, Gessain A, Grünfeld JP, Hermine O: Retinoic acid for treatment of multicentric Castleman's disease. The Lancet 1999, 354:1262-1263.
13. Lee FC, Merchant SH: Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. American Journal of Hematology 2003, 73:48-53.
14. Marcelin AG, Aaron L, Mateus C, Gyan E, Gorin I, Viard JP, Calvez V, Dupin N: Rituximab therapy for HIV-associated Castleman's disease. Blood 2003, 102:2786-2788.
15. Ide M, Kawachi Y, Izumi Y, Kasagi K, Ogino T: Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab. Eur J Haematol 2006, 76 (2):119-23.
16. Gérard L, Bérezné A, Galicier L, Meignin V, Obadia M, De Castro N, Jacomet C, Verdon R, Madelaine-Chambrin I, Boulanger E, Chevret S, Agbalika F, Oksenhendler E: Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 Castlema. B Trial J Clin Oncol 2007, 25 (22):3350-3356.
17. Powles T, Stebbing J, Montot S: Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman's disease. Blood 2007, 110 (12):4132-4133.
18. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC: A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
19. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005, 23:630-639.